Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.25), $0.19 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $190.7 million versus the consensus estimate of $206.03 million.

GUIDANCE:

Myriad Genetics sees FY2026 revenue of $770-790 million, versus the consensus of $863.6 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.